

Antibody Drug Conjugates (ADC) Market to Hit USD 29.10 Billion by 2032, Driven by Rising Cancer Cases

Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and Strategic Collaborations

AUSTIN, TX, UNITED STATES, February 5, 2025 /EINPresswire.com/ --

According to Research by SNS Insider, The global [Antibody Drug Conjugates Market](#), valued at USD 10.28 billion in 2023, is expected to reach USD 29.10 billion by 2032, growing at a CAGR of

12.29% during the forecast period from 2024 to 2032. The market expansion is largely driven by the rising adoption of ADCs for targeted cancer therapies, their ability to deliver potent cytotoxic drugs directly to cancer cells, and ongoing advancements in ADC technologies.


Regulatory Support and Technological Advancements Drives the Market Growth

The governments across the globe and the key regulatory bodies, such as the FDA and EMA, are fully supporting the development and commercialization of ADCs by expediting the approvals of the most promising ADC therapies. By April 2024, another ADC targeting a new biomarker was approved by U.S. FDA (Food and Drug Administration) for advanced lung cancer, confirming the ADC science has become more mature.

Technological advancements such as linker technology and more effective payloads which are likely to increase the effectiveness of ADCs are expected to spur the growth of the market. By employing these innovations, it is possible to severely increase the concentration of the drug at the desired area, while drastically reducing these side effects and hence treatment outcome.

Get a Free Sample Report of Antibody Drug Conjugates Market @ <https://www.snsinsider.com/sample-request/4421>

Segmental Analysis



Antibody Drug Conjugates Market

- By Application, Breast cancer held the largest market share around 48% market share in 2023

It is due to increasing incidence, pipeline availability and high uptake of Kadcyra. The approved drugs for breast cancer are Trodelvy, Enhertu, and Kadcyra. Early breast cancer patients have been bolstered by the addition of Kadcyra and the recently approved Enhertu and Trodelvy should provide a boost to the segment.

- By Target, HER2, or human epidermal growth factor receptor 2, held the largest segment of the market in 2023.

This is essential in breast cancer treatment for which overexpression is frequently seen. ADC's are powerful drugs that are targeted to HER2, and can be delivered directly to the cancer cell, leading to enhanced activity against the cancer cell while sparing normal cells. It has a lot to do with that, which is why the uptake is substantial and that's driven this part of the industry as the leader.

- By Product Kadcyra dominated the ADC market in 2023

It is driven by a rising breast cancer incidence and a multitude of breast cancer-specific ADC approvals. A green signal by F. Hoffmann-La Roche Ltd. for use in China, a new high-growth market, gave a significant boost to Kadcyra in January 2022. Kadcyra wide uptake also underscores an expanding market for targeted cancer protagonists, the biggest ADC addressable incremental revenue-generating market.

- Regional Analysis North America Held the Largest Market Share of Around 51% in 2023.

North America, particularly the United States, is the dominant region in the ADC market, owing to the strong presence of major pharmaceutical companies, the well-established healthcare infrastructure, and increasing cancer cases. Moreover, favorable reimbursement policies, robust research and development activities, and significant government funding for cancer treatments have all contributed to the region's growth.

Need any customization research on Antibody Drug Conjugates Market, Enquire Now @

<https://www.snsinsider.com/enquiry/4421>

Antibody Drug Conjugates Market Segmentation

By Application

- Blood Cancer
 - o Leukemia
 - o Lymphoma
 - o Multiple Myeloma
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer

By Product

- Kadcyła
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Others

By Target

- HER2
- CD22
- CD30
- Others

By Technology

- Type
 - o Cleavable Linker
 - o Non-cleavable Linker
 - o Linkerless
- Linker Technology Type
 - o VC
 - o Sulfo-SPDB
 - o VA
 - o Hydrazone
 - o Others
- Payload Technology
 - o MMAE
 - o MMAF
 - o DM4
 - o Camptothecin
 - o Others

Key Players in Antibody Drug Conjugates Market

- Genentech (Herceptin, Kadcyła)
- Seagen Inc. (Adcetris, Tivdak)
- AstraZeneca (Enhertu, Lumoxiti)
- Daiichi Sankyo (Enhertu, DS-8201)
- Pfizer (Besponsa, Mylotarg)
- ImmunoGen (Mirvetuximab soravtansine, Epotuzumab)
- Bristol Myers Squibb (Empliciti, Opdivo + Yervoy)
- Amgen (Blincyto, Omecamtiv mecarbil)
- ADC Therapeutics (Lonca, Zynlonta)
- MacroGenics (Margetuximab, Enoblituzumab)

- Bayer (BAY 94-9343, Fresenius Kabi ADC)
- Zymeworks (Zymeworks 857, ZW49)
- Gilead Sciences (Yescarta, Kymriah)
- Mersana Therapeutics (XMT-1536, XMT-1592)
- Boehringer Ingelheim (M-Tor, BI 836880)
- Sanofi (SAR408701, SAR566658)
- Eli Lilly (Mirvetuximab soravtansine, Tiragolumab)
- Janssen Biotech (Darzalex, Balversa)
- Roche (Tecentriq, Gazyva)
- Curis Inc. (CA-170, CI-8993)

Table of Contents – Major Key Points

1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Antibody Drug Conjugates Market by Application
8. Antibody Drug Conjugates Market by Product
9. Antibody Drug Conjugates Market by Target
10. Antibody Drug Conjugates Market by Technology
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion

Speak with Our Expert Analyst Today to Gain Deeper Insights @
<https://www.snsinsider.com/request-analyst/4421>

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave

SNS Insider Pvt. Ltd

+1 315 636 4242

[email us here](#)

Visit us on social media:

Facebook
X
LinkedIn
Instagram

This press release can be viewed online at: <https://www.einpresswire.com/article/783274138>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.